7/9/2015

Orion upgrades full-year outlook for 2015

ORION CORPORATION      STOCK EXCHANGE RELEASE  9 JULY 2015 at  11.15 a.m. EEST              

 

Orion upgrades full-year outlook for 2015


Orion Corporation upgrades the full-year outlook estimate for 2015 provided on 24 April 2015. Net sales of the first half of 2015 was EUR 515 million and operating profit of the first half of 2015 EUR 157 million. Based on the good start for the year the company estimates that the full-year net sales and operating profit will be higher than estimated previously.

New full-year outlook estimate for 2015, provided on 9 July 2015

Net sales is estimated to be at similar level to 2014 (net sales were EUR 1,015 million in 2014).


Operating profit is estimated to exceed EUR 260 million.


The Group's capital expenditure will be about EUR 50 million excluding substantial corporate or product acquisitions. (The Group's capital expenditure was EUR 57 million in 2014).

Previous full-year outlook estimate for 2015, provided on 24 April 2015

Net sales will be slightly lower than in 2014 (net sales were EUR 1,015 million in 2014).


Operating profit is estimated to exceed EUR 230 million.


The Group's capital expenditure will be about EUR 50 million excluding substantial corporate or product acquisitions. (The Group's capital expenditure was EUR 57 million in 2014).

Orion will publish the Interim Report January-June 2015 on Tuesday, 28 July 2015.
  
Orion Corporation

Timo Lappalainen
President and CEO
  Olli Huotari
SVP, Corporate Functions
 

                                                                       
Contact person:
Timo Lappalainen, CEO
tel. +358 50 966 3692

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02101 Espoo, Finland
Homepage: www.orion.fi

Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs.


Orion's net sales in 2014 amounted to EUR 1,015 million and the Company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ Helsinki.